|
SSH2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62889999999472E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.27770000036121E-07 |
| Normal-vs-Stage2 |
2.399000E-04 |
| Normal-vs-Stage3 |
6.94929999989213E-07 |
| Normal-vs-Stage4 |
8.39309999944859E-07 |
| Stage1-vs-Stage2 |
6.967400E-01 |
| Stage1-vs-Stage3 |
1.568380E-01 |
| Stage1-vs-Stage4 |
1.007560E-01 |
| Stage2-vs-Stage3 |
5.445400E-01 |
| Stage2-vs-Stage4 |
3.337000E-01 |
| Stage3-vs-Stage4 |
5.479000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.7790000007607E-08 |
| Normal-vs-AfricanAmerican |
8.73650000121629E-08 |
| Normal-vs-Asian |
1.777650E-04 |
| Caucasian-vs-AfricanAmerican |
1.592480E-02 |
| Caucasian-vs-Asian |
9.605200E-01 |
| AfricanAmerican-vs-Asian |
6.820300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65968999999988E-05 |
| Normal-vs-Female |
1.33010000002987E-06 |
| Male-vs-Female |
6.123200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.95229999999858E-05 |
| Normal-vs-Age(41-60Yrs) |
6.7600000042134E-08 |
| Normal-vs-Age(61-80Yrs) |
1.74800000030118E-07 |
| Normal-vs-Age(81-100Yrs) |
2.970400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.362640E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.591980E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.592400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.795200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.994600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.884600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.917800E-02 |
| Classical-VS-Follicular |
1.844010E-02 |
| Classical-VS-Other |
1.428240E-01 |
| Classical-VS-Normal |
1.32279999998097E-06 |
| Tall-VS-Follicular |
7.035400E-01 |
| Tall-VS-Other |
5.529200E-01 |
| Tall-VS-Normal |
1.38409999994593E-06 |
| Follicular-VS-Other |
4.540600E-01 |
| Follicular-VS-Normal |
3.55650000005703E-07 |
| Other-VS-Normal |
4.1781000000074E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.38870000019476E-07 |
| Normal-vs-N1 |
1.04530000000214E-06 |
| N0-vs-N1 |
4.234600E-01 |
|
|
